Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 76

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Methotrexate Compared to Placebo for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Desoximetasone
  • Sponsor:Medac Gesellschaft fuer klinische Spezialpraeparate mbH

Systemic lupus erythematosus

Not recruiting

Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate
  • Sponsor:Galapagos

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Dermatitis atopic

Not recruiting

Study on SAR444656 for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Conjunctivitis allergic+1

Not recruiting

Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Aluminium Hydroxide
  • Sponsor:HAL Allergy B.V.

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Colitis ulcerative

Not recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.